AbbVie Inc. (ABBV)

ABBV's $2.1 billion Capstan deal and 20+ recent acquisitions sharpen its pipeline edge across immunology and beyond.

AbbVie's $2.1 billion Capstan deal brings a novel in-vivo CAR-T therapy and tLNP platform to boost its immunology pipeline.

Seeing Machines Ltd (AIM:SEE, OTC:SEEMF), the UK-listed tech firm specialising in driver monitoring systems, is picking up speed with its next-generation aftermarket product. Stifel notes that the Gua...

Abbvie Inc (NYSE:ABBV) has agreed to acquire Capstan Therapeutics in a deal worth up to $2.1 billion, expanding its pipeline with a potential first-in-class treatment for autoimmune diseases and gaini...

AbbVie said on Monday it will acquire Capstan Therapeutics in a deal worth up to $2.1 billion, adding experimental treatments for autoimmune diseases to its portfolio.

Inflation isn't just back, it's becoming policy. From skewed CPI data to deficit-driven dollar moves, we're entering a new and lasting macro era. The U.S. may now prefer higher inflation to fix its ba...

Dividend Aristocrats have underperformed the S&P 500 in 2025, with NOBL up 1.77% versus SPY's 5.55% year-to-date gain. Dividend growth remains healthy, with 44 out of 69 Aristocrats already raising pa...

Buy, sell, or hold? That's the question investors must continually ask about each stock in their portfolio.

I don't know if we'll be riding in personal aircraft 20 years from now, like George Jetson did in the cartoon TV series. I don't know if artificial intelligence (AI) will replace millions of jobs.

AbbVie (ABBV) closed at $182.31 in the latest trading session, marking a -2.4% move from the prior day.